A systematic review of 8 preclinical studies found 11 venom-derived antimicrobial peptides that reduced death and bacterial load from multidrug-resistant Acinetobacter baumannii infections in animal models.
11 AMPs from 8 studiesEleven venom-derived antimicrobial peptides, mostly from arthropods, reduced lethality and bacterial load in preclinical models of MDR Acinetobacter baumannii — the WHO's top-priority pathogen
What the researchers found
The systematic review identified 8 preclinical studies testing 11 different animal venom-derived antimicrobial peptides against MDR Acinetobacter baumannii. Most AMPs originated from arthropod venoms (scorpions, spiders), and all were positively charged and rich in lysine residues.
In vivo testing showed these peptides reduced MDR-Ab-induced lethality and bacterial load across three infection models: invasive (bacteremia and pneumonia) and superficial (wound infections). Critically, the venom-derived AMPs demonstrated pleiotropic effects beyond direct bacterial killing — including pro-healing, anti-inflammatory, and antioxidant activities — that contribute to infection treatment and tissue recovery.
Why it matters
Acinetobacter baumannii is classified by the WHO as the number one critical-priority pathogen for which new antibiotics are urgently needed. Some strains are resistant to every available antibiotic. Venom-derived antimicrobial peptides offer several advantages: they kill bacteria through membrane disruption (making resistance development difficult), they work against MDR strains, and their additional anti-inflammatory and healing properties address the tissue damage that accompanies severe infections.
How the study worked
Systematic review following PRISMA guidelines. The authors searched for preclinical studies evaluating animal venom-derived antimicrobial peptides against MDR Acinetobacter baumannii infections in vivo. Eight studies meeting inclusion criteria were analyzed for AMP characteristics (charge, amino acid composition, venom source), antimicrobial activity, in vivo efficacy across different infection models, and additional biological activities.
What this study cannot tell us
All 8 included studies are preclinical (animal models), with no human clinical data. The review found only 8 qualifying studies, reflecting the early stage of this research area. The specific infection models, peptide doses, and animal species varied across studies, making direct comparisons difficult. Manufacturing scalability and cost for venom-derived peptides are not addressed. Potential toxicity at therapeutic doses in humans requires investigation. The review focused specifically on MDR-Ab and may not reflect efficacy against other resistant pathogens.
How to read the evidence
This is a systematic review following PRISMA guidelines, which adds methodological rigor. However, all 8 included studies are preclinical (animal models), and the small number of qualifying studies reflects the early stage of this research area. The consistent positive results across different peptides and infection models is encouraging but must be validated in human trials.
When this study was published
Published in 2023, this systematic review captures the current state of venom-derived AMP research against one of the most dangerous resistant pathogens. The field is active and new studies are expected to build on these findings.
The bigger picture
The antimicrobial resistance crisis demands fundamentally different approaches to fighting bacteria. Venom-derived AMPs represent millions of years of evolutionary optimization — these peptides have been perfected by natural selection to defend against microbes. This systematic review demonstrates that the evidence base, while preclinical, is consistent and growing. The multifunctional nature of these peptides (killing bacteria while also healing tissue and reducing inflammation) positions them as potentially superior to conventional antibiotics that only target the pathogen.
Questions still open
- Which of the 11 identified AMPs is most promising for clinical development — based on efficacy, safety profile, and manufacturing feasibility?
- Could synthetic analogs of these venom-derived peptides improve on the natural sequences for human therapeutic use?
- Would combining venom-derived AMPs with conventional antibiotics produce synergistic effects against MDR-Ab?
Common questions
Why is Acinetobacter baumannii so dangerous?
Why might venom peptides work when antibiotics don't?
Read the original research
Therapeutic Prospection of Animal Venoms-Derived Antimicrobial Peptides against Infections by Multidrug-Resistant Acinetobacter baumannii: A Systematic Review of Pre-Clinical Studies.
Toxins, 15(4)
Citation
Lima, William Gustavo; de Lima, Maria Elena. (2023). Therapeutic Prospection of Animal Venoms-Derived Antimicrobial Peptides against Infections by Multidrug-Resistant Acinetobacter baumannii: A Systematic Review of Pre-Clinical Studies.. Toxins, 15(4). https://doi.org/10.3390/toxins15040268